Molecular approaches to thyroid cancer diagnosis

Endocrine-Related Cancer

Volumn 21, Issue 5, 2014, Pages T301-T313

  Hsiao, Susan J ^a   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Molecular marker; Prognostic marker; Thyroid cancer; Thyroid nodule

Indexed keywords

TUMOR MARKER;

FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MUTATION; THYROID NEOPLASMS;

BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; THYROID NEOPLASMS;

EID: 84907502941     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0166     Document Type: Article

References (111)

1. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW & Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. American Journal of Surgical Pathology 30 216-222. (doi:10.1097/01.pas.0000176432.73455.1b)
2. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J et al. 2013 Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism 98 E364-E369. (doi:10.1210/jc.2012-2703)
3. Albores-Saavedra J, Henson DE, Glazer E & Schwartz AM 2007 Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype - papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocrine Pathology 18 1-7. (doi:10.1007/s12022-007-0002-z)
4. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ et al. 2012 Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. New England Journal of Medicine 367 705-715. (doi:10.1056/NEJMoa1203208)
5. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, Parker C, Steward DL, Mandel SJ & Haugen BR 2014 Multicenter clinical experience with the Afirma gene expression classifier. Journal of Clinical Endocrinology and Metabolism 99 119-125. (doi:10.1210/jc.2013-2482)
6. Ali SZ & Cibas ES 2010 The Bethesda System for Reporting Thyroid Cytopathology Definitions, Criteria and Explanatory Notes, Eds SZ Ali & ES Cibas. New York: Springer.
7. Baloch ZW, Fleisher S, LiVolsi VA & Gupta PK 2002 Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagnostic Cytopathology 26 41-44. (doi:10.1002/dc.10043)
8. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK & Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagnostic Cytopathology 36 425-437. (doi:10.1002/dc.20830)
9. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G et al. 2008 Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncology 9 543-549. (doi:10.1016/S1470-2045(08)70132-3)
10. Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P et al. 1997 Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. American Journal of Human Genetics 61 1123-1130. (doi:10.1086/301610)
11. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S & Pierotti MA 1998 RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clinical Cancer Research 4 223-228.
12. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH & Montori V 2013 Prevalence of thyroid cancer in multinodular goiter vs. single nodule: a systematic review and meta-analysis. Thyroid 23 449-455. (doi:10.1089/thy.2012.0156)
13. Burgess JR & Tucker P 2006 Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16 47-53. (doi:10.1089/thy.2006.16.47)
14. Burns JS, Blaydes JP, Wright PA, Lemoine L, Bond JA, Williams ED & Wynford-Thomas D 1992 Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression. Molecular Carcinogenesis 6 129-139. (doi:10.1002/mc.2940060208)
15. Buryk MA, Monaco SE, Witchel SF, Mehta DK, Gurtunca N, Nikiforov YE & Simons JP 2013 Preoperative cytology with molecular analysis to help guide surgery for pediatric thyroid nodules. International Journal of Pediatric Otorhinolaryngology 77 1697-1700. (doi:10.1016/j.ijporl.2013.07.029)
16. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L et al. 2010 Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. Journal of Clinical Endocrinology and Metabolism 95 1365-1369. (doi:10.1210/jc.2009-2103)
17. Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, Levillain P, Romeo G & Bonneau D 1998 A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. American Journal of Human Genetics 63 1743-1748. (doi:10.1086/302164)
18. Cavaco BM, Batista PF, Martins C, Banito A, do Rosario F, Limbert E, Sobrinho LG & Leite V 2008 Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocrine-Related Cancer 15 207-215. (doi:10.1677/ERC-07-0214)
19. Charkes ND 2006 On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid 16 181-186. (doi:10.1089/thy.2006.16.181)
20. Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP & Nikiforov Y 2009 A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocrine Pathology 20 122-126. (doi:10.1007/s12022-009-9073-3)
21. Chudova D, Wilde JI, Wang ET, Wang H, Rabbee N, Egidio CM, Reynolds J, Tom E, Pagan M, Ted Rigl C et al. 2010 Molecular classification of thyroid nodules using high-dimensionality genomic data. Journal of Clinical Endocrinology and Metabolism 95 5296-5304. (doi:10.1210/jc.2010-1087)
22. Ciampi R & Nikiforov YE 2005 Alterations of the BRAF gene in thyroid tumors. Endocrine Pathology 16 163-172. (doi:10.1385/EP:16:3:163)
23. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA & Nikiforov YE 2005 Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. Journal of Clinical Investigation 115 94-101. (doi:10.1172/JCI23237)
24. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW & Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute 95 625-627. (doi:10.1093/jnci/95.8.625)
25. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 1167-1214. (doi:10.1089/thy.2009.0110)
26. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C et al. 1997 Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Research 57 4710-4713.
27. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167. (doi:10.1001/jama.295.18.2164)
28. Dobashi Y, Sugimura H, Sakamoto A, Mernyei M, Mori M, Oyama T & Machinami R 1994 Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagnostic Molecular Pathology 3 9-14. (doi:10.1097/00019606-199403010-00003)
29. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G & Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 91 1753-1760. (doi:10.1172/JCI116385)
30. Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB & McIver B 2012 The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid 22 996-1001. (doi:10.1089/thy.2012.0180)
31. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C & Zedenius J 2003 Involvement of the PAX8/peroxisome proliferator-activated receptor g rearrangement in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 4440-4445. (doi:10.1210/jc.2002-021690)
32. Fagin JA 2002 Minireview: Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Molecular Endocrinology 16 903-911. (doi:10.1210/mend.16.5.0838)
33. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184. (doi:10.1172/JCI116168)
34. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL & Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. Journal of Clinical Endocrinology and Metabolism 85 1170-1175. (doi:10.1210/jcem.85.3.6472)
35. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7440. (doi:10.1038/sj.onc.1207980)
36. French CA, Alexander EK, Cibas ES, Nose V, Laguette J, Faquin W, Garber J, Moore F Jr, Fletcher JA, Larsen PR et al. 2003 Genetic and biological subgroups of low-stage follicular thyroid cancer. American Journal of Pathology 162 1053-1060. (doi:10.1016/S0002-9440(10)63902-8)
37. Frich L, Glattre E & Akslen LA 2001 Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiology, Biomarkers & Prevention 10 113-117.
38. Garcia-Jimenez C & Santisteban P 2007 TSH signalling and cancer. Arquivos Brasileiros de Endocrinologia e Metabologia 51 654-671. (doi:10.1590/S0004-27302007000500003)
39. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL & Tallini G 2001 β-Catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. American Journal of Pathology 158 987-996. (doi:10.1016/S0002-9440(10)64045-X)
40. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J & Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research 65 10199-10207. (doi:10.1158/0008-5472.CAN-04-4259)
41. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L & Vitti P 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Journal of Endocrinological Investigation 33 51-56. (doi:10.1007/BF03346587)
42. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 557-563. (doi:10.1016/0092-8674(90)90659-3)
43. de Groot JW, Links TP, Plukker JT, Lips CJ & Hofstra RM 2006 RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 27 535-560. (doi:10.1210/er.2006-0017)
44. Gustafson S, Zbuk KM, Scacheri C & Eng C 2007 Cowden syndrome. Seminars in Oncology 34 428-434. (doi:10.1053/j.seminoncol.2007.07.009)
45. Guth S, Theune U, Aberle J, Galach A & Bamberger CM 2009 Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. European Journal of Clinical Investigation 39 699-706. (doi:10.1111/j.1365-2362.2009.02162.x)
46. Hansford JR & Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. Journal of Medical Genetics 37 817-827. (doi:10.1136/jmg.37.11.817)
47. Harrell RM & Bimston DN 2014 Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Endocrine Practice 20 364-369. (doi:10.4158/EP13330.OR)
48. He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J & de la Chapelle A 2009 A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24. Cancer Research 69 625-631. (doi:10.1158/0008-5472.CAN-08-1071)
49. Hemminki K, Eng C & Chen B 2005 Familial risks for nonmedullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 5747-5753. (doi:10.1210/jc.2005-0935)
50. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K et al. 2013 TERT promoter mutations in familial and sporadic melanoma. Science 339 959-961. (doi:10.1126/science.1230062)
51. Hou P, Liu D & Xing M 2007a Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6 377-379. (doi:10.4161/cc.6.3.3818)
52. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G et al. 2007b Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170. (doi:10.1158/1078-0432.CCR-06-1125)
53. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z et al. 2013 SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
54. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339 957-959. (doi:10.1126/science.1229259)
55. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C et al. 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine Journal 56 89-97. (doi:10.1507/endocrj.K08E-208)
56. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ & Nikiforov YE 2014 The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. Journal of Clinical Endocrinology and Metabolism 99 E276-E285. (doi:10.1210/jc.2013-2503)
57. Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, Gandhi M, Carty SE, Hodak SP, Luo J et al. 2014 Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. PNAS 111 4233-4238. (doi:10.1073/pnas.1321937111)
58. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R et al. 2012 A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clinical Cancer Research 18 2032-2038. (doi:10.1158/1078-0432.CCR-11-2487)
59. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ & Shong YK 2005 The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology 63 588-593. (doi:10.1111/j.1365-2265.2005.02389.x)
60. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
61. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M et al. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19 565-612. (doi:10.1089/thy.2008.0403)
62. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 98 E1562-E1566. (doi:10.1210/jc.2013-2383)
63. Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy LY, Mabuchi K, Tronko MD & Nikiforov YE 2013 RET/PTC and PAX8/PPARg chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer 119 1792-1799. (doi:10.1002/cncr.27893)
64. Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, Bogdanova TI, Evdokimova VN, Hatch M, Zurnadzy LY, Nikiforova MN et al. 2014 ETV6-NTRK3 is a common chromosomal rearrangement in radiationassociated thyroid cancer. Cancer 120 799-807. (doi:10.1002/cncr.28484)
65. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B & Wynford-Thomas D 1989 High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4 159-164.
66. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC & Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clinical Endocrinology 63 461-466. (doi:10.1111/j.1365-2265.2005.02367.x)
67. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK & Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Journal of Clinical Endocrinology and Metabolism 93 3106-3116. (doi:10.1210/jc.2008-0273)
68. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & Xu D 2013a The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. (doi:10.1038/onc.2013.446)
69. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & Xing M 2013b Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603-610. (doi:10.1530/ERC-13-0210)
70. Malchoff CD & Malchoff DM 2006 Familial nonmedullary thyroid carcinoma. Cancer Control 13 106-110.
71. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, Arnold A & Malchoff DM 2000 Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. Journal of Clinical Endocrinology and Metabolism 85 1758-1764. (doi:10.1210/jcem.85.5.6557)
72. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG & Leite V 2002 Expression of PAX8-PPARg1 rearrangements in both follicular thyroid carcinomas and adenomas. Journal of Clinical Endocrinology and Metabolism 87 3947-3952. (doi:10.1210/jcem.87.8.8756)
73. Mazeh H & Sippel RS 2013 Familial nonmedullary thyroid carcinoma. Thyroid 23 1049-1056. (doi:10.1089/thy.2013.0079)
74. Mazzaferri EL 1992 Thyroid cancer in thyroid nodules: finding a needle in the haystack. American Journal of Medicine 93 359-362. (doi:10.1016/0002-9343(92)90163-6)
75. Mazzaferri EL 1993 Management of a solitary thyroid nodule. New England Journal of Medicine 328 553-559. (doi:10.1056/NEJM199302253280807)
76. Mazzaferri EL & Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 418-428. (doi:10.1016/0002-9343(94)90321-2)
77. McKay JD, Lesueur F, Jonard L, Pastore A, Williamson J, Hoffman L, Burgess J, Duffield A, Papotti M, Stark M et al. 2001 Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. American Journal of Human Genetics 69 440-446. (doi:10.1086/321979)
78. Melo M, Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C et al. 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E754-E765. (doi:10.1210/jc.2013-3734)
79. Monaco SE, Pantanowitz L, Khalbuss WE, Benkovich VA, Ozolek J, Nikiforova MN, Simons JP & Nikiforov YE 2012 Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration. Cancer Cytopathology 120 342-350. (doi:10.1002/cncy.21199)
80. Moses W, Weng J& Kebebew E 2011 Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid 21 367-371. (doi:10.1089/thy. 2010.0256)
81. Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T & Machinami R 2000 Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathology, Research and Practice 196 1-7. (doi:10.1016/S0344-0338(00)80015-1)
82. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M et al. 1995 Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Journal of Internal Medicine 238 343-346. (doi:10.1111/j.1365-2796.1995.tb01208.x)
83. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF & Klempnauer J 2000 Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 128 984-993. (doi:10.1067/msy.2000.110845)
84. Namba H, Rubin SA & Fagin JA 1990 Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Molecular Endocrinology 4 1474-1479. (doi:10.1210/mend-4-10-1474)
85. Nikiforov YE 2006 RET/PTC rearrangement - a link between Hashimoto's thyroiditis and thyroid cancer. or not. Journal of Clinical Endocrinology and Metabolism 91 2040-2042. (doi:10.1210/jc.2006-0791)
86. Nikiforov YE & Ohori NP 2012 Follicular carcinoma. In Diagnostic Pathology and Molecular Genetics of the Thyroid, 2nd edn, pp 152-182. Eds YE Nikiforov, PW Biddinger & LDR Thompson. Philadelphia: Lippincott Williams & Wilkins.
87. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H & Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research 57 1690-1694.
88. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K & Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. Journal of Clinical Endocrinology and Metabolism 94 2092-2098. (doi:10.1210/jc.2009-0247)
89. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, Yip L, Seethala RR, Tublin ME, Stang MT et al. 2011 Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. Journal of Clinical Endocrinology and Metabolism 96 3390-3397. (doi:10.1210/jc.2011-1469)
90. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG & Nikiforov YE 2002 PAX8-PPAR g rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. American Journal of Surgical Pathology 26 1016-1023. (doi:10.1097/00000478-200208000-00006)
91. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW II, Tallini G, Kroll TG & Nikiforov YE 2003 RAS point mutations and PAX8-PPAR g rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318-2326. (doi:10.1210/jc.2002-021907)
92. Nikiforova MN, Wald AI, Roy S, Durso MB & Nikiforov YE 2013 Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 98 E1852-E1860. (doi:10.1210/jc.2013-2292)
93. Nishihara E, Amino N, Maekawa K, Yoshida H, Ito M, Kubota S, Fukata S & Miyauchi A 2009 Prevalence of TSH receptor and Gsa mutations in 45 autonomously functioning thyroid nodules in Japan. Endocrine Journal 56 791-798. (doi:10.1507/endocrj.K09E-073)
94. Ohori NP & Schoedel KE 2011 Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: sources and recommendations. Acta Cytologica 55 492-498. (doi:10.1159/000334218)
95. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D & Klugbauer S 2000 Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clinical Cancer Research 6 1093-1103.
96. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 . Cancer Research 69 4885-4893. (doi:10.1158/0008-5472.CAN-09-0727)
97. Roy S, Durso MB, Wald A, Nikiforov YE & Nikiforova MN 2014 SeqReporter: automating next-generation sequencing result interpretation and reporting workflow in a clinical laboratory. Journal of Molecular Diagnostics 16 11-22. (doi:10.1016/j.jmoldx.2013.08.005)
98. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G & Fusco A 1994 Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 509-516.
99. Shay JW & Bacchetti S 1997 A survey of telomerase activity in human cancer. European Journal of Cancer 33 787-791. (doi:10.1016/S0959-8049(97)00062-2)
100. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580. (doi:10.1038/sj.onc.1206706)
101. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C & Monier R 1990 Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5 565-570.
102. Tanaka K, Sonoo H, Saito W, Ohta Y, Shimo T, Sohda M, Yamamoto Y & Kurebayashi J 2011 Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma. ISRN Endocrinology 2011 308029. (doi:10.5402/2011/308029)
103. Tomaz RA, Sousa I, Silva JG, Santos C, Teixeira MR, Leite V & Cavaco BM 2012 FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clinical Endocrinology 77 926-933. (doi:10.1111/j.1365-2265.2012.04505.x)
104. Tufano RP, Teixeira GV, Bishop J, Carson KA & Xing MB 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 91 274-286. (doi:10.1097/MD.0b013e31826a9c71)
105. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B & Papotti MG 2004 Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 100 950-957. (doi:10.1002/cncr.20087)
106. Xing MB 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Reviews 28 742-762. (doi:10.1210/er.2007-0007)
107. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M et al. 2009 BRAF mutation testing of thyroid fineneedle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. Journal of Clinical Oncology 27 2977-2982. (doi:10.1200/JCO.2008.20.1426)
108. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM et al. 2013 Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Journal of the American Medical Association 309 1493-1501. (doi:10.1001/jama.2013.3190)
109. Yip L, Wharry L, Armstrong M, Silbermann A, McCoy KL, Stang MT, Ohori NP, LeBeau SO, Coyne C, Nikiforova MN et al. 2014 A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Annals of Surgery 260 163-168. (doi:10.1097/SLA.0000000000000215)
110. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH & Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American Journal of Clinical Pathology 120 71-77. (doi:10.1309/ND8D9LAJTRCTG6QD)
111. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M & Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. Journal of Clinical Endocrinology and Metabolism 91 3603-3610.(doi:10.1210/jc.2006-1006)